Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating atrophic age related macular degeneration

A macular degeneration and dryness technology, applied in the directions of pharmaceutical formulations, organic active ingredients, medical preparations with non-active ingredients, etc., can solve the problem that AMD has no effective treatment and other problems

Inactive Publication Date: 2011-08-17
ALLERGAN INC
View PDF21 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, "there is no effective therapy for the most prevalent atrophic (dry) form of AMD"

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating atrophic age related macular degeneration
  • Method for treating atrophic age related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Intravitreal bevacizumab-PLGA microspheres for the treatment of dry AMD

[0104] A 78-year-old man presented with age-related macular degeneration and cataracts in both eyes. The patient also had a history of cardiovascular disease and an inferior myocardial infarction 6 months earlier. The patient complained of blurred vision and metamorphopsia in the right eye. On examination, the visual acuity was 20 / 400 in the right eye and 20 / 32 in the left eye. Retinal examination revealed subfoveal choroidal neovascularization (CNV) in the right eye (wet AMD in the right eye), approximately 1 optic disc area in size with peripheral hemorrhage and edema. The opposite left eye showed high-risk features for developing wet AMD, such as drusen with soft amorphous appearance in the fovea but no evidence of choroidal neovascularization, and was confirmed by fluorescein angiography (left eye dry AMD) . The patient started with monthly intravitreal injections of bevacizumab (an anti-...

Embodiment 2

[0111] Low-dose intravitreal bevacizumab-PLGA microspheres for the treatment of dry AMD

[0112] A 74-year-old male was diagnosed with age-related AMD in one (right) eye and wet AMD in the other (left) eye. His right eye vision was 20 / 40. He was treated by intravitreal injection of a sustained release drug delivery system into a dry AMD eye. The sustained release drug delivery system contained a total of about 6 micrograms (low dose) of the active agent bevacizumab in a polymeric carrier. The polymer carrier is high viscosity hyaluronic acid or PLGA or PLA, which is combined with the bevacizumab anti-neovascular agent to form a plurality of microspheres or a single integrated implant in which the bevacizumab is uniformly distributed . Alternatively, the sustained-release drug delivery system may comprise bevacizumab microspheres or implants in hyaluronic acid (cross-linked or non-cross-linked) such that there is simultaneous viscous polymerization in the same drug deliver...

Embodiment 3

[0114] Intravitreal ranibizumab-PLGA microspheres for the treatment of dry AMD

[0115] An 83-year-old woman woke up with blurred vision in her left eye. She has a history of glaucoma, s / p cataract removal with IOL (intraocular lens), and dry AMD in both eyes, and is taking Alphagan P eye drops. The patient was examined by her ophthalmologist, who was diagnosed with wet AMD in the left eye and was immediately sent to a retinal specialist. Vision is 20 / 25 in the right eye and 20 / 200 in the left eye. Retinal examination revealed dry changes in the macula of the right eye, but high-risk features such as large drusen and numerous pigmented changes in the subfoveal area. The macula of the left eye showed subfoveal CNV, approximately 2 discs in size, with surrounding macular edema and intraretinal hemorrhage. Fluorescein angiography confirmed the presence of a very typical looking left eye CNV. Monthly intravitreal injections of ranibizumab into this patient's wet AMD left eye...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

Description

[0001] cross reference [0002] This application claims the benefit of US Nonprovisional Patent Application No. 12 / 176,238, filed July 18, 2008, the entire disclosure of which is hereby specifically incorporated by reference. Background technique [0003] The present invention relates to compositions (ie, drug delivery systems) and methods for treating ocular disorders and preventing the occurrence of certain ocular disorders. In particular, the present invention relates to pharmaceutical compositions and methods for, for example, the prevention of retinal, choroidal and / or macular Neovascularization is used to treat and prevent conditions at the back of the eye, and / or to treat various types of macular degeneration (eg, age-related macular degeneration). [0004] In industrialized societies, the average life expectancy is over 80 years and increasing. Unfortunately, the quality of life of the elderly is often significantly reduced due to an eye condition known as age-relate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/34A61K47/38A61K47/36A61P27/02
CPCA61K9/1647A61K9/1652A61K9/0051A61K9/1635A61K45/00A61K47/34A61K47/36A61K47/38A61K31/712A61K2039/505C07K16/22A61P27/02A61P9/00A61K39/395A61K31/573A61K47/08A61K9/0048
Inventor M·R·罗宾逊W·M·布兰达P·M·休斯J·A·伯克S·M·惠特卡普
Owner ALLERGAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com